A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model

Trial Profile

A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs AL 53817 (Primary) ; AL 78843 (Primary) ; Dexamethasone
  • Indications Allergic conjunctivitis; Ragweed pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 28 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Jul 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top